MCID: ESS001
MIFTS: 58

Essential Tremor

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Essential Tremor

MalaCards integrated aliases for Essential Tremor:

Name: Essential Tremor 54 12 50 25 51 29 52 42 14 69
Benign Essential Tremor 12 50 25
Tremor, Hereditary Essential, 1 50 69
Hereditary Essential Tremor 1 24 29
Hereditary Essential Tremor 50 25
Familial Tremor 25 69
Etm1 50 71
Essential Tremor, Susceptibility to 13
Tremor Hereditary Essential, 1 50
Tremor, Hereditary Essential 1 71
Tremor Familial Essential, 1 50
Essential Hereditary Tremor 12
Familial Essential Tremor 50
Presenile Tremor Syndrome 50
Shaky Hand Syndrome 12
Fet1 50

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
progressive disorder
age at onset ranges from 50 to 70 years
penetrance is usually complete by age 65 years
favorable response to alcohol in about 50%
prevalence of essential tremor ranges from 0.4 to 6% in the general population


HPO:

32
essential tremor:
Onset and clinical course progressive
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 190300
Disease Ontology 12 DOID:4990
ICD10 33 G25.0
MeSH 42 D020329
MedGen 40 C1860861
UMLS 69 C0270736

Summaries for Essential Tremor

NINDS : 51 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary : Essential Tremor, also known as benign essential tremor, is related to personality disorder and sensorineural hearing loss-early graying-essential tremor syndrome, and has symptoms including dysarthria, postural tremor and hand tremor. An important gene associated with Essential Tremor is DRD3 (Dopamine Receptor D3), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and tongue, and related phenotypes are behavior/neurological and cellular

NIH Rare Diseases : 50 essential tremor is the most common movement disorder.  it is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. it is distinguished from tremor that results from other disorders or known causes, such as tremors seen with parkinson disease or head trauma. most cases of essential tremor are hereditary. there are five forms of essential tremor that are based on different genetic causes. several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. in mild cases, treatment may not be necessary. in cases where symptoms interfere with daily living, medications may help to relieve symptoms.      last updated: 9/12/2014

UniProtKB/Swiss-Prot : 71 Tremor, hereditary essential 1: A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles also may be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.

Genetics Home Reference : 25 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

OMIM : 54
Essential tremor may be the most common human movement disorder. The main feature of essential tremor is postural tremor of the arms, but the head, legs, trunk, voice, jaw, and facial muscles also may be involved. Aggravated by emotions, hunger, fatigue, and temperature extremes, the condition may cause a functional disability or even incapacitation. Autosomal dominant inheritance can be demonstrated in most families (summary by Higgins et al., 1997). Deng et al. (2007) provided a detailed review of the genetics of essential tremor. (190300)

Disease Ontology : 12 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Wikipedia : 72 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is the... more...

Related Diseases for Essential Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 2 Essential Tremor
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 5
Tremor, Hereditary Essential, 4

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 personality disorder 28.7 DRD3 FMR1 SLC6A3 SNCA
2 sensorineural hearing loss-early graying-essential tremor syndrome 12.0
3 tremor 11.6
4 tremor, hereditary essential, 5 11.5
5 mental retardation, autosomal recessive 48 11.0
6 tremor, hereditary essential, 4 11.0
7 tremor, nystagmus, and duodenal ulcer 11.0
8 x-linked dystonia-parkinsonism/lubag 10.8
9 nephronophthisis-like nephropathy 1 10.8
10 13q12.3 microdeletion syndrome 10.5 LRRK2 SNCA
11 microcephaly 18, primary, autosomal dominant 10.3 SLC6A3 SNCA
12 dystonia 10.2
13 riedel's fibrosing thyroiditis 10.2 LRRK2 SNCA
14 hyperekplexia, hereditary 1, autosomal dominant or recessive 10.2 SLC1A2 SNCA
15 pyromania 10.2 DRD3 SLC6A3
16 trichuriasis 10.1 HS1BP3 PRKN
17 piebald trait, kit-related 10.1 LRRK2 SNCA
18 erb-duchenne and dejerine-klumpke palsies 10.1 PRKN SNCA
19 sebaceous gland disease 10.1 LRRK2 SLC6A3 SNCA
20 cervicitis 10.0
21 cervical dystonia 10.0
22 ataxia 10.0
23 ovarian cystadenocarcinoma 10.0 SLC1A2 SLC6A3 SNCA
24 neuronitis 9.9
25 multiple system atrophy 9.9
26 dementia 9.9
27 restless legs syndrome 9.9
28 parkinson disease 10 9.9 LRRK2 PRKN SNCA
29 sparc-related osteogenesis imperfecta 9.9 LRRK2 PRKN SNCA
30 waldenstroem's macroglobulinemia 9.8 LRRK2 PRKN SNCA
31 mast syndrome 9.8 LRRK2 PRKN SNCA
32 ectodermal dysplasia 13, hair/tooth type 9.8 LRRK2 PRKN SNCA
33 sarcoma 9.8
34 cerebritis 9.8
35 apraxia 9.6
36 thyroiditis 9.6
37 obsessive-compulsive personality disorder 9.6
38 muscular atrophy 9.6
39 cerebellar ataxia 9.6
40 social phobia 9.6
41 cerebellar degeneration 9.6
42 spinocerebellar ataxia 1 9.6
43 hypothyroidism 9.6
44 alzheimer disease 9.6
45 autonomic dysfunction 9.6
46 normal pressure hydrocephalus 9.6
47 hypotonia 9.6
48 obsessive-compulsive disorder 9.6
49 epilepsy 9.6
50 lateral sclerosis 9.6

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to Essential Tremor

Symptoms & Phenotypes for Essential Tremor

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
dysarthria
tremor, action (arms, tongue, head, legs and trunk)
tremor, postural (arms, tongue, head, legs and trunk)
fine rapid hand tremor, 4-12 hz


Clinical features from OMIM:

190300

Human phenotypes related to Essential Tremor:

32
id Description HPO Frequency HPO Source Accession
1 dysarthria 32 HP:0001260
2 postural tremor 32 HP:0002174
3 hand tremor 32 HP:0002378

UMLS symptoms related to Essential Tremor:


essential and other specified forms of tremor, tremor, senile tremor, action tremor, physiological tremor

MGI Mouse Phenotypes related to Essential Tremor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 DRD3 FMR1 HTRA2 LRRK2 PRKN SLC1A2
2 cellular MP:0005384 9.56 FMR1 HTRA2 LRRK2 PRKN SLC1A2 SLC6A3
3 nervous system MP:0003631 9.28 SLC6A3 SNCA TENM4 DRD3 FMR1 HTRA2

Drugs & Therapeutics for Essential Tremor

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Iodine Investigational Phase 4 7553-56-2 807
7 Dopamine Agents Phase 4,Phase 3
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
11 Antiparkinson Agents Phase 4,Phase 3
12 Excitatory Amino Acid Antagonists Phase 4
13 Excitatory Amino Acids Phase 4
14 Analgesics Phase 4,Phase 2,Phase 3
15 Anti-Anxiety Agents Phase 4
16 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
17 calcium channel blockers Phase 4,Phase 2
18 Calcium, Dietary Phase 4,Phase 2
19 Psychotropic Drugs Phase 4
20 Tranquilizing Agents Phase 4
21 Adrenergic Agents Phase 4,Phase 2,Phase 3
22 Adrenergic Antagonists Phase 4
23 Adrenergic beta-Antagonists Phase 4
24 Anti-Arrhythmia Agents Phase 4
25 Antihypertensive Agents Phase 4
26 Botulinum Toxins Phase 4,Phase 3,Phase 2
27 Cholinergic Agents Phase 4,Phase 3,Phase 2
28 Vasodilator Agents Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 2
30 cadexomer iodine Phase 4
31 Calamus Nutraceutical Phase 4
32
Cocaine Approved, Illicit Phase 3 50-36-2 5760 446220
33
Topiramate Approved Phase 3 97240-79-4 5284627
34
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
35 Anesthetics Phase 3,Phase 2
36 Anesthetics, Local Phase 3
37 Dopamine Uptake Inhibitors Phase 3
38 Neurotransmitter Uptake Inhibitors Phase 3
39 Vasoconstrictor Agents Phase 3
40 Anti-Obesity Agents Phase 3
41 Neuroprotective Agents Phase 3,Phase 1,Phase 2
42 Protective Agents Phase 3,Phase 2,Phase 1
43 abobotulinumtoxinA Phase 3,Phase 2
44 Botulinum Toxins, Type A Phase 3,Phase 2
45 onabotulinumtoxinA Phase 3,Phase 2
46 Antioxidants Phase 3,Phase 2
47 Dopamine agonists Phase 3
48 Adrenergic Agonists Phase 2, Phase 3
49 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
50 Adrenergic alpha-Agonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 132)

id Name Status NCT ID Phase Drugs
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4 l-123 Ioflupane
2 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
3 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
4 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
5 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
6 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
7 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
8 Atlas Predicted DBS Settings in Essential Tremor Enrolling by invitation NCT02678429 Phase 4
9 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
10 Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor Unknown status NCT00724906 Phase 3 123 I - ALTROPANE®
11 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
12 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause. Completed NCT00236496 Phase 3 topiramate
13 Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
14 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
15 Pre-lemniscal Radiation Deep Brain Stimulation for ET Terminated NCT00634478 Phase 2, Phase 3
16 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor Withdrawn NCT01441284 Phase 3 pramipexole;placebo
17 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
18 A Safety/Efficacy Trial of Zonisamide for Essential Tremor Completed NCT00223743 Phase 2 Zonisamide
19 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
20 A Pilot Efficacy and Safety Study of ST101 in Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
21 A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
22 Octanol to Treat Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
23 Efficacy of Levetiracetam in Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
24 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
25 Evaluate SAGE-547 in Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
26 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
27 Botulinum Toxin A to Treat Arm Tremor Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo
28 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Placebo pill
29 Effect of Alcohol on Tremors Completed NCT00001925 Phase 2 Alcohol
30 Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment Recruiting NCT02551848 Phase 2 Botulinum toxin type A (Xeomin®)
31 A Phase 2 RCT Study of CX-8998 for Essential Tremor Recruiting NCT03101241 Phase 2 CX-8998
32 A Study to Evaluate SAGE-217 in Subjects With Essential Tremor Recruiting NCT02978781 Phase 2 SAGE-217;Placebo
33 Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres? Recruiting NCT02960243 Phase 1, Phase 2
34 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Recruiting NCT01945567 Phase 2
35 Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study Recruiting NCT02585583 Phase 2
36 An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor Active, not recruiting NCT02668146 Phase 2 Perampanel;Placebo
37 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Enrolling by invitation NCT02427646 Phase 2 IncobotulinumtoxinA
38 A Study of T2000 in Essential Tremor Terminated NCT00321087 Phase 2 T2000;T2000;T2000
39 T2000 in Essential Tremor - Open Label Continuation Terminated NCT00655278 Phase 2 T2000
40 Octanoic Acid for Essential Tremor Completed NCT01468948 Phase 1 Octanoic Acid
41 1-Octanol to Treat Essential Tremor Completed NCT00016679 Phase 1 1-Octanol
42 1-Octanol to Treat Essential Tremor Completed NCT00001986 Phase 1 1-Octanol
43 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT02037217 Phase 1
44 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT01304758 Phase 1
45 Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders Completed NCT01698450 Phase 1
46 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial Recruiting NCT02558634 Phase 1
47 Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor Unknown status NCT01446939
48 Tremor Monitoring Device Unknown status NCT02523807
49 Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes Unknown status NCT00368199 Early Phase 1
50 Decision-making and Emotion Recognition in Essential Tremor Completed NCT01223144

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

Genetic tests related to Essential Tremor:

id Genetic test Affiliating Genes
1 Hereditary Essential Tremor 1 29 24 DRD3
2 Essential Tremor 29

Anatomical Context for Essential Tremor

MalaCards organs/tissues related to Essential Tremor:

39
Brain, Cerebellum, Tongue, Cortex, Testes, Thalamus, Eye

Publications for Essential Tremor

Articles related to Essential Tremor:

(show top 50) (show all 719)
id Title Authors Year
1
Mutation analysis of CHCHD2 gene in Chinese Han familial essential tremor patients and familial Parkinson's disease patients. ( 27814991 )
2017
2
A data mining approach using cortical thickness for diagnosis and characterization of essential tremor. ( 28526878 )
2017
3
Non-invasive Brain Stimulation for Essential Tremor. ( 28373927 )
2017
4
Essential tremor & Parkinson disease: Recognizing the differences. ( 28926496 )
2017
5
Letter: Thalamotomy-Like Effects From Partial Removal of a Ventral Intermediate Nucleus Deep Brain Stimulator Lead in a Patient With Essential Tremor: Case Report. ( 28379503 )
2017
6
Topography of essential tremor. ( 28442304 )
2017
7
Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. ( 28409750 )
2017
8
Cerebellar pathology in childhood-onset vs. adult-onset essential tremor. ( 28867587 )
2017
9
Coronal Transcranial Sonography and M-Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. ( 28426143 )
2017
10
Relationship between GWAS-linked three new loci in Essential tremor and risk of Parkinson's disease in Chinese population. ( 28807494 )
2017
11
Assessment of Three New Loci from Genome-wide Association Study in Essential Tremor in Chinese population. ( 28801652 )
2017
12
Cognitive Dysfunction Is Associated with Greater Imbalance and Falls in Essential Tremor. ( 28469597 )
2017
13
Emerging strategies in the management of essential tremor. ( 28382111 )
2017
14
Awareness of cognitive impairment in individuals with essential tremor. ( 28477687 )
2017
15
Role of altered cerebello-thalamo-cortical network in the neurobiology of essential tremor. ( 28062908 )
2017
16
The ice test to differentiate essential tremor from Parkinson's disease tremor. ( 28946133 )
2017
17
Topiramate for essential tremor. ( 28409827 )
2017
18
Equivalence of cell survival data for radiation dose and thermal dose in ablative treatments: analysis applied to essential tremor thalamotomy by focused ultrasound and gamma knife. ( 28044461 )
2017
19
Nonmotor Symptoms in Essential Tremor and Other Tremor Disorders. ( 28805576 )
2017
20
The Experience of Essential Tremor Caregivers: Burden and Its Correlates. ( 28855888 )
2017
21
Quality improvement in neurology: Essential Tremor Quality Measurement Set. ( 28835402 )
2017
22
Early Head Tremor in Essential Tremor: A Case Series and Commentary. ( 28373926 )
2017
23
Feasibility study: Effect of hand resistance exercise on handwriting in Parkinson's disease and essential tremor. ( 28389133 )
2017
24
Brain positron emission tomography with 2-(18)F-2-deoxi-D-glucose of patients with dystonia and essential tremor detects differences between these disorders. ( 28805131 )
2017
25
Is Essential tremor a single entity? ( 28905504 )
2017
26
Heterotopic Purkinje Cells: a Comparative Postmortem Study of Essential Tremor and Spinocerebellar Ataxias 1, 2, 3, and 6. ( 28791574 )
2017
27
Differential Diagnosis of Parkinson Disease, Essential Tremor, and Enhanced Physiological Tremor with the Tremor Analysis of EMG. ( 28884038 )
2017
28
Nursing Management of the Patient Undergoing Focused Ultrasound: A New Treatment Option for Essential Tremor. ( 28817495 )
2017
29
Thalamic DBS with a constant-current device in essential tremor: AA controlled clinical trial. ( 28400200 )
2017
30
Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. ( 28503363 )
2017
31
A Network Model of Local Field Potential Activity in Essential Tremor and the Impact of Deep Brain Stimulation. ( 28068428 )
2017
32
Comparative Evaluation of Magnetic Resonance-Guided Focused Ultrasound Surgery for Essential Tremor. ( 28810261 )
2017
33
A computerized tablet system for evaluating treatment of essential tremor by magnetic resonance guided focused ultrasound. ( 28412948 )
2017
34
Zonisamide for essential tremor. ( 28836659 )
2017
35
Emotion modulation of the startle reflex in essential tremor: Blunted reactivity to unpleasant and pleasant pictures. ( 27887893 )
2017
36
General and selective brain connectivity alterations in essential tremor: A resting state fMRI study. ( 28913163 )
2017
37
Action Tremor Asymmetry Profile Does Not Aggregate in Families with Essential Tremor. ( 28469594 )
2017
38
Efficacy of Fiber Tractography in the Stereotactic Surgery of the Thalamus for Patients with Essential Tremor. ( 28458383 )
2017
39
Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. ( 28841694 )
2017
40
Depression and social phobia in essential tremor and Parkinson's disease. ( 28948077 )
2017
41
Hierarchical Dynamic Causal Modeling of Resting-State fMRI Reveals Longitudinal Changes in Effective Connectivity in the Motor System after Thalamotomy for Essential Tremor. ( 28775707 )
2017
42
Support System to Improve Reading Activity in Parkinson's Disease and Essential Tremor Patients. ( 28467366 )
2017
43
Toward quantitative characterization of essential tremor for future tremor suppression. ( 28813814 )
2017
44
Probabilistic mapping of deep brain stimulation effects in essential tremor. ( 27981031 )
2017
45
Heart rate variability to differentiate essential tremor from early-stage tremor-dominant Parkinson's disease. ( 27538602 )
2016
46
Time reproduction deficits in essential tremor patients. ( 27091412 )
2016
47
A suggested minimum standard deep brain stimulation evaluation for essential tremor. ( 26944141 )
2016
48
Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. ( 27545646 )
2016
49
A Trial of Focused Ultrasound Thalamotomy for Essential Tremor. ( 27959760 )
2016
50
Precise stimulation location optimizes speech outcomes in essential tremor. ( 27595548 )
2016

Variations for Essential Tremor

Expression for Essential Tremor

Search GEO for disease gene expression data for Essential Tremor.

Pathways for Essential Tremor

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.86 FMR1 LRRK2 PRKN SLC1A2 SNCA
2 10.95 HTRA2 LRRK2 PRKN SLC6A3 SNCA
3 10.84 PRKN SLC6A3 SNCA

GO Terms for Essential Tremor

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.67 FUS LRRK2 SLC6A3 SNCA
2 growth cone GO:0030426 9.58 FMR1 LRRK2 SNCA
3 perikaryon GO:0043204 9.5 FMR1 FUS LRRK2
4 inclusion body GO:0016234 9.43 LRRK2 SNCA
5 presynapse GO:0098793 9.43 FMR1 PRKN SLC6A3
6 neuron projection GO:0043005 9.35 FMR1 LRRK2 PRKN SLC6A3 TENM4
7 postsynapse GO:0098794 9.33 FMR1 LRRK2 SNCA
8 axon GO:0030424 9.02 FMR1 LRRK2 SLC1A2 SLC6A3 SNCA

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.89 DRD3 SLC1A2 SLC6A3 SNCA
2 aging GO:0007568 9.83 HTRA2 SLC6A3 SNCA
3 locomotory behavior GO:0007626 9.76 DRD3 PRKN SLC6A3
4 cellular response to oxidative stress GO:0034599 9.75 HTRA2 LRRK2 SNCA
5 mitochondrion organization GO:0007005 9.74 HTRA2 LRRK2 PRKN
6 negative regulation of protein phosphorylation GO:0001933 9.71 LRRK2 PRKN SNCA
7 adult locomotory behavior GO:0008344 9.67 HTRA2 PRKN SNCA
8 regulation of multicellular organism growth GO:0040014 9.65 DRD3 HTRA2
9 regulation of reactive oxygen species metabolic process GO:2000377 9.64 PRKN SNCA
10 regulation of canonical Wnt signaling pathway GO:0060828 9.64 LRRK2 PRKN
11 behavioral response to cocaine GO:0048148 9.63 DRD3 SNCA
12 regulation of neuron death GO:1901214 9.63 LRRK2 SNCA
13 response to cocaine GO:0042220 9.63 DRD3 SLC6A3 SNCA
14 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.62 LRRK2 PRKN
15 positive regulation of proteasomal protein catabolic process GO:1901800 9.62 FMR1 PRKN
16 cellular protein catabolic process GO:0044257 9.61 HTRA2 PRKN
17 cellular response to dopamine GO:1903351 9.61 LRRK2 PRKN
18 prepulse inhibition GO:0060134 9.6 DRD3 SLC6A3
19 regulation of dopamine secretion GO:0014059 9.58 DRD3 PRKN SNCA
20 dopamine biosynthetic process GO:0042416 9.56 SLC6A3 SNCA
21 regulation of dopamine metabolic process GO:0042053 9.55 PRKN SLC6A3
22 synaptic transmission, dopaminergic GO:0001963 9.54 DRD3 PRKN SNCA
23 protein localization to mitochondrion GO:0070585 9.52 LRRK2 PRKN
24 cellular response to manganese ion GO:0071287 9.51 LRRK2 PRKN
25 regulation of neurotransmitter secretion GO:0046928 9.5 FMR1 PRKN SNCA
26 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 DRD3 LRRK2
27 negative regulation of neuron death GO:1901215 9.46 HTRA2 LRRK2 PRKN SNCA
28 regulation of synaptic vesicle transport GO:1902803 9.43 LRRK2 PRKN
29 dopamine metabolic process GO:0042417 9.43 DRD3 PRKN SNCA
30 protein homotrimerization GO:0070207 9.35 HTRA2
31 regulation of locomotion GO:0040012 9.13 DRD3 LRRK2 SNCA
32 dopamine uptake involved in synaptic transmission GO:0051583 8.8 PRKN SLC6A3 SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.54 FMR1 LRRK2 SNCA
2 Hsp70 protein binding GO:0030544 9.32 PRKN SNCA
3 dynein complex binding GO:0070840 9.26 FMR1 SNCA
4 phospholipase binding GO:0043274 9.16 PRKN SNCA
5 identical protein binding GO:0042802 9.1 FMR1 FUS HTRA2 LRRK2 PRKN SNCA
6 dopamine binding GO:0035240 8.96 DRD3 SLC6A3

Sources for Essential Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....